Diabetic Macular Edema – Pipeline Review, H2 2017
A new research document with title ‘Diabetic Macular Edema – Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as F. Hoffmann-La Roche Ltd, Formycon AG, Genmab A/S, GlaxoSmithKline Plc…………….The report will help user gain market insights, future trends and growth prospects for Review, H2 2017
Description about Diabetic Macular Edema
The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.
Request a sample report @ https://www.htfmarketreport.com/sample-report/593283-diabetic-macular-edema-pipeline-review-1
The Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
– The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=593283
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
ActiveSite Pharmaceuticals Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Alcon Laboratories Inc
Ampio Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
EyeGate Pharmaceuticals Inc
- Hoffmann-La Roche Ltd
Icon Bioscience Inc
Kala Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Kowa Company Ltd
Ocular Therapeutix Inc
Ohr Pharmaceutical Inc
Regeneron Pharmaceuticals Inc
SciFluor Life Sciences LLC
Senju Pharmaceutical Co Ltd
Stealth BioTherapeutics Inc
Xbrane Biopharma AB
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/593283-diabetic-macular-edema-pipeline-review-1
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Diabetic Macular Edema – Overview 8
Diabetic Macular Edema – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Diabetic Macular Edema – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Diabetic Macular Edema – Companies Involved in Therapeutics Development 29
Aciont Inc 29
ActiveSite Pharmaceuticals Inc 29
Acucela Inc 30
Aerie Pharmaceuticals Inc 30
Aerpio Therapeutics Inc 31
Alcon Laboratories Inc 31
Allergan Plc 32
Ampio Pharmaceuticals Inc 32
Araim Pharmaceuticals Inc 33
Boehringer Ingelheim GmbH 33
Cell Medica Ltd 34
Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
Clearside BioMedical Inc 35
Coherus BioSciences Inc 35
EyeGate Pharmaceuticals Inc 36
- Hoffmann-La Roche Ltd 36
Formycon AG 37
Genmab A/S 37
GlaxoSmithKline Plc 38
Icon Bioscience Inc 38
Kala Pharmaceuticals Inc 39
Kalvista Pharmaceuticals Inc 39
Kowa Company Ltd 40
Lupin Ltd 40
Mabion SA 41
Ocular Therapeutix Inc 41
Oculis ehf 42
Ohr Pharmaceutical Inc 42
Pfizer Inc 43
pSivida Corp 43
Regeneron Pharmaceuticals Inc 44
SciFluor Life Sciences LLC 44
Senju Pharmaceutical Co Ltd 45
Stealth BioTherapeutics Inc 45
ThromboGenics NV 46
Verseon Corp 46
Xbrane Biopharma AB 47
Diabetic Macular Edema – Drug Profiles 48
(aflibercept + nesvacumab) – Drug Profile 48
abicipar pegol – Drug Profile 50
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/593283-diabetic-macular-edema-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218